Overseas regulatory announcements: Filing of Form F-3

Hong Kong, Shanghai & Florham Park, NJ: Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today filed the Form F-3 Registration Statement with the U.S. Securities and Exchange Commission.  This filing follows the expiration of the previous Form F-3 Registration Statement filed in 2020. The Form F-3 is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3865U_1-2024-6-28.pdf and also on the website of the Company at www.hutch-med.com.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/​immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

CONTACTS